Jaime Sanz

Profesor asociado asistencial

Universidad Católica de Valencia Facultad de Medicina

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jaime Sanz is an Associate Professor at the Universitat de Valencia Facultad de Medicina in Spain. His research primarily focuses on hematologic malignancies, particularly advances in CAR T-cell therapy, stem cell transplantation, and outcomes related to acute myeloid leukemia. Recent publications include studies on patient selection for CAR T-cell therapy and the impact of donor characteristics in stem cell transplantation. He is actively involved in research that addresses treatment protocols and prognostic factors in hematologic conditions.

Articles (27)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (10)

William Ying Khee Hwang

Professor and Chair

Duke-NUS Medical School

SINGAPORE

View details

Jordi Esteve Reyner

Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)

SPAIN

View details

Per Ljungman

Karolinska University Hospital

SWEDEN

View details

Carlos Solano

Professor of Medicine

Universitat Politècnica de València

SPAIN

View details

Suhag Parikh

Emory University

UNITED STATES

View details

Didier Blaise

Professor of Medicine

Aix-Marseille University

FRANCE

View details

Javier Marco-Ayala

Universidad de Murcia

SPAIN

View details

Alessandro Rambaldi

University of Milan

ITALY

View details

Thomas Pabst

SWITZERLAND

View details

Jurgen Kuball

UMC Utrecht

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jaime Sanz

Research Interests

Explore related searches

Contact this professor

About

Articles (27)

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia‐Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party

Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on behalf of GETH-TC

Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT

Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy

Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT.

Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study

Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies

Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy

Post-Transplantation Cyclophosphamide-Based Graft-versusHost Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Single-Unit Transfusion Policy in Autologous Hematopoietic Stem Cell Transplantation: Less is Not Worse.

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials

Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Extracorporeal Photopheresis in Graft-versus-Host Disease

Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT

Post‐transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA‐mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT

Post-transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA-mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT

Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT

Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Collaborators (10)

William Ying Khee Hwang

Jordi Esteve Reyner

Per Ljungman

Carlos Solano

Suhag Parikh

Didier Blaise

Javier Marco-Ayala

Alessandro Rambaldi

Thomas Pabst

Jurgen Kuball

Make your next move.